Downregulation of CDK6 leads to inhibition of pancreatic cancer cell metastatic capacity, whereas increased CDK6 expression was observed in pancreatic cancer clinical samples and was associated with poor prognosis (27). This evidence concerns the gene CDK6 and familial pancreatic carcinoma.